Mantle cell lymphoma (MCL) is the aggressive subtype of non-Hodgkin's lymphoma with the poorest long-term survival probability. Although a high percentage of patients may achieve CR with first-line chemotherapy, 1 disease progression and relapses do occur. No satisfactory therapeutic options exist in advanced or relapsed disease. 2 In a previous paper, 3 we reported the results of a 22-month follow-up after a high-dose chemotherapy regimen associated with Rituximab in-vivo purging and autologous hematopoietic SCT (R-HDS regimen, Figure 1 ): at that time, projected EFS and overall surival (OS) at 3 years were 75 and 85%, respectively . We followed 28 newly diagnosed MCL patients in that study (Table 1) . This report is a 10-year follow-up analysis evaluating the clinical outcomes of those patients.
Data on the survival of the patients treated with R-HDS was obtained for 27 patients at the time of the analysis (January 2008; one patient was lost to follow-up). Twenty out of the original 28 patients (71.4%) were alive at the time of data analysis. The median OS had not been reached (Figure 2a ), even after stratification according to Mantle Cell Lymphoma International Prognostic Index (MIPI). 4 Of the 20 survivors, 14 (50%) remained alive and in CR.
Three patients (10.7%) had experienced relapses, which were treated with Rituximab plus conventional chemotherapy. Of these three relapses, two are now in CR, and one is in PR. Another patient (3.6%) who had experienced a relapse was treated with allogenic BMT and now has stable disease (SD). Two patients (7.2%) experienced molecular relapses, who were treated with Rituximab. 5 Of the two patients with molecular relapses, one is in CR, and one has SD. Median EFS has not been reached for low-risk group (Figure 2b G-CSF on day þ 4 (5 mg/kg) to begin the stem cell mobilization process; Rituximab (375 mg/sm) 48 h following CTX and 24 h before the first stem cell harvest; Ara-C, 24 g/sm over 6 days (2 g/sm every 12 h) followed by stem cell reinfusion 1 (minimum 2 Â 10 6 CD34 þ cells/kg); Rituximab (375 mg/sm) immediately before reinfusion 1 and 24 h before the second stem cell harvest; melphalan (MEL) 180 mg/sm followed by reinfusion 2 (minimum 3 Â 10 6 CD34 þ cells/kg); mitoxantrone (60 mg/sm) plus MEL (180 mg/sm) (Mito-Mel) for myeloablation followed by reinfusion 3 (minimum 5 Â 10 6 CD34 þ cells/kg); Rituximab (375 mg/sm) approximately 25 and 38 days following the final stem cell reinfusion. two (7.1%) from cardiac events; one (3.6%) from pulmonary infection and one (3.6%) from myelodysplastic syndrome. Of note, even after the present follow-up, we did not observe an increase in secondary malignancies, whereas other regimens reported up to a 6% increase. 6 A possible limitation of these encouraging results is that they might reflect, as do the majority of phase II trials, a biased selection of younger and clinically fit patients, and/ or they might include, by chance, predominantly low-risk MCL patients. However, the study enrolled a series of consecutive patients, with the expected distribution of the different prognostic categories (that is, 14 low-risk, 11 intermediate-risk and 2 high-risk patients according to their MIPI score). 4 The R-HDS regimen appears to be a very effective dose-intense chemoimmunotherapy program for MCL. In particular, our data (10-year OS, 68% for intermediate/ high-risk group, 76% for low-risk group; EFS, 34 and 57%, respectively) compare favorably with long-term reports from other groups who have used immunotherapy in association with dose-intense chemotherapy 6 (hyper-CVAD; 5-year OS, 65%; EFS, 48%), even though a stratification based on MIPI score would have helped in the comparison of the results; in addition, they are in agreement with data obtained after a shorter (6-year) follow-up with a similar chemoimmunotherapy strategy. 7 A direct comparison with data obtained in conventionally treated patients, as those reported recently by Determan et al., 8 is impossible for the short follow-up of these patients.
In conclusion, these data obtained after a longer followup and a more precise prognostic stratification confirm the important role of dose-intensive therapy in the frontline treatment of MCL. To our knowledge, although on a relatively small number of patients, this is the longest follow-up reported in a dose-intense therapy program for MCL patients. While awaiting the availability of new, more tolerable regimens incorporating new agents (such as bortezomib 9 and mTOR inhibitors) 10 to improve clinical results particularly in high-risk patients, we can confidently offer this treatment with curative intent to younger patients. 
